Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Clofarabine Produces Durable Remissions in Older Patients with AML with Unfavorable Prognostic Factors and Multiple Comorbidities.

Stefan Faderl, MD, Harry P Erba, David F. Claxton, M.D., M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, MD, Janice Gabrilove, MD, Elizabeth Anderson, Elly Barry, MD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 4155.

https://doi.org/10.1182/blood.V114.22.4155.4155

Published: 2009

Journal Articles

Outpatient Treatment with Clofarabine in a Phase II Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia (AML).

David F. Claxton, M.D., Thomas J Myers, MD, FACP, Harry P Erba, Stefan Faderl, MD, M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, MD, Janice Gabrilove, MD, Clay R Warnock, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 4162.

https://doi.org/10.1182/blood.V114.22.4162.4162

Published: 2009

Journal Articles

Complete Response to Clofarabine Is Durable and Correlates with Survival in Previously Untreated Older Adult Patients with Acute Myeloid Leukemia (AML) and Unfavorable Prognostic Factors.

Janice Gabrilove, MD, Stefan Faderl, MD, Harry P Erba, David F. Claxton, M.D., M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, MD, Stephen Eckert, Ph.D, Dirk Huebner, MD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 2061.

https://doi.org/10.1182/blood.V114.22.2061.2061

Published: 2009

Journal Articles

Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are ≥ 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors.

Harry P Erba, Stefan Faderl, MD, David F. Claxton, M.D., M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, MD, Janice Gabrilove, MD, Stephen Eckert, Ph.D, Dirk Huebner, MD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 2083.

https://doi.org/10.1182/blood.V114.22.2083.2083

Published: 2009

Journal Articles

Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy

Harry Paul Erba, MD, PhD, Hagop Kantarjian, David F. Claxton, MD, M. Arellano, Roger M Lyons, MD, Tibor J. Kovacsovics, MD, Janice Gabrilove, MD, Stephen Eckert, Ph.D, Rekha Abichandani, MD, Stefan Faderl, MD

Blood (2008) 112 (11): 558.

https://doi.org/10.1182/blood.V112.11.558.558

Published: 2008

NARROW

Clofarabine Produces Durable Remissions in Older Patients with AML with Unfavorable Prognostic Factors and Multiple Comorbidities.

Outpatient Treatment with Clofarabine in a Phase II Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia (AML).

Complete Response to Clofarabine Is Durable and Correlates with Survival in Previously Untreated Older Adult Patients with Acute Myeloid Leukemia (AML) and Unfavorable Prognostic Factors.

Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are ≥ 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors.

Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Clofarabine Produces Durable Remissions in Older Patients with AML with Unfavorable Prognostic Factors and Multiple Comorbidities.

Outpatient Treatment with Clofarabine in a Phase II Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia (AML).

Complete Response to Clofarabine Is Durable and Correlates with Survival in Previously Untreated Older Adult Patients with Acute Myeloid Leukemia (AML) and Unfavorable Prognostic Factors.

Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are ≥ 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors.

Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only